LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

A study of LEO 32731 in the treatment of psoriasis vulgaris

This is an investigation of the efficacy of LEO 32731 30 mg as compared to placebo after 16 weeks of oral treatment of psoriasis vulgaris

Inclusion Criteria:

• Signed and dated informed consent
• Aged between 18 years and 65.
• Males or females of non-childbearing potential.
• Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis
• Have moderate to severe psoriasis vulgaris
• Candidates of systemic anti-psoriatic treatment and/or phototherapy

Exclusion Criteria:

• Subjects with therapy resistant psoriasis
• Previously exposed to apremilast
• Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris
• Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris